| Market Cap | 5.02M | P/E | 0.01 | EPS this Y | -3,730.20% | Ern Qtrly Grth | - |
| Income | -120.25k | Forward P/E | -0.52 | EPS next Y | 7.00% | 50D Avg Chg | -13.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -79.00% |
| Dividend | N/A | Price/Book | 0.39 | EPS next 5Y | - | 52W High Chg | -96.00% |
| Recommedations | 2.00 | Quick Ratio | 2.16 | Shares Outstanding | 1.63M | 52W Low Chg | 15.00% |
| Insider Own | 0.32% | ROA | -61.08% | Shares Float | 1.63M | Beta | 0.12 |
| Inst Own | 1.96% | ROE | -3.12% | Shares Shorted/Prior | 32.81K/47.93K | Price | 0.83 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 232,706 | Target Price | 32.13 |
| Oper. Margin | - | Earnings Date | May 20 | Volume | 105,693 | Change | -1.16% |
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TIDMARSH GEORGE F | Director Director | Oct 16 | Sell | 0.6501 | 1,845 | 1,199 | 27,771 | 10/18/23 |
| TIDMARSH GEORGE F | Director Director | Sep 28 | Sell | 0.69 | 1,429 | 986 | 42,096 | 10/02/23 |
| TIDMARSH GEORGE F | Director Director | Sep 14 | Sell | 0.74 | 25,500 | 18,870 | 39,348 | 09/18/23 |
| TIDMARSH GEORGE F | Director Director | Feb 25 | Buy | 1.60 | 20,000 | 32,000 | 467,156 | 02/28/22 |
| TIDMARSH GEORGE F | Director Director | Feb 08 | Buy | 2.55 | 31,000 | 79,050 | 447,156 | 02/10/22 |
| TIDMARSH GEORGE F | Director Director | Feb 04 | Buy | 2.46 | 50,000 | 123,000 | 1,523,335 | 02/08/22 |